First‑Line Pharmacologic Management of Hypertension

General First‑Line Recommendations

• Initiate therapy for uncomplicated hypertension with a thiazide or thiazide‑like diuretic (chlorthalidone or indapamide preferred over hydrochlorothiazide), a long‑acting dihydropyridine calcium‑channel blocker, an ACE inhibitor, or an ARB; all four classes are Grade A, Class I, Level A agents providing equivalent cardiovascular protection according to the 2025 American College of Cardiology/American Heart Association (ACC/AHA) guideline. 1

• The ACC/AHA guideline classifies these four drug classes as first‑line therapy with Class I, Level A evidence. 1

• Compared with placebo, each of the four first‑line classes demonstrably reduces cardiovascular events, stroke, and mortality in patients with hypertension. 1

Population‑Specific Recommendations

Black Patients

• ACE inhibitors should not be used as first‑line monotherapy in Black patients (Grade A recommendation against) because they achieve ≈51 % less stroke risk reduction than thiazides or dihydropyridine CCBs. 2, 3, 4
• In Black patients, thiazide diuretics and dihydropyridine CCBs are preferred first‑line agents, while ACE inhibitors or ARBs may be employed as second‑line agents or in combination therapy. (Grade A/Grade B) 2, 3

Older Adults (≥ 60 years)

• Beta‑blockers are not recommended as first‑line therapy in patients aged ≥ 60 years (Grade A recommendation against) because they are less effective at preventing stroke and cardiovascular events than thiazides, CCBs, ACE inhibitors, or ARBs. 2, 3, 4, 5
• Beta‑blockers may be used as first‑line therapy in patients younger than 60 years (Grade B). 2, 3, 4
• Regardless of age, beta‑blockers remain appropriate for patients with compelling indications (post‑myocardial infarction, heart‑failure with reduced ejection fraction, or angina). 2, 3

Isolated Systolic Hypertension (SBP ≥ 130 mm Hg, DBP < 80 mm Hg)

• Preferred first‑line agents are thiazide or thiazide‑like diuretics (Grade A), long‑acting dihydropyridine CCBs (Grade A), and ARBs (Grade B). 3
• Beta‑blockers and alpha‑blockers should be avoided as first‑line therapy in this population (Grade A recommendation against). 3

Combination Therapy Guidelines

• When systolic BP is ≥ 20 mm Hg above target or diastolic BP is ≥ 10 mm Hg above target—typically when BP ≥ 150/90 mm Hg while aiming for <130/80 mm Hg—initiate treatment with two first‑line agents, preferably as a single‑pill combination. (Class I, Level A) 2, 3, 4, 1

• Recommended two‑drug combinations (all Grade A or B):

• Do not combine an ACE inhibitor with an ARB (Grade A recommendation against) because this increases the risk of hyperkalemia, syncope, and acute kidney injury without additional cardiovascular benefit. 2, 3, 4

Agents to Avoid as First‑Line Therapy

• Alpha‑blockers are not recommended as first‑line therapy for uncomplicated hypertension (Grade A recommendation against) due to inferior cardiovascular protection compared with thiazides. 2, 3, 4

• Non‑dihydropyridine calcium‑channel blockers (diltiazem, verapamil) should not be combined with beta‑blockers because of a heightened risk of severe bradycardia and heart block. (Grade A) 2, 3

First‑Line Antihypertensive Drug Recommendations

Thiazide‑type Diuretics

• Grade A recommendation – All major Canadian, ACC/AHA, and European guidelines endorse thiazide or thiazide‑like diuretics as the preferred initial monotherapy for uncomplicated hypertension. [6][7][8][9]10
• The 2017 ACC/AHA guideline highlights long‑acting agents (e.g., chlorthalidone) as optimal first‑step therapy because they provide superior cardiovascular‑event prevention compared with other classes. Class I, Level A. 11
• The 2024 ESC guideline prefers thiazide‑like agents (chlorthalidone or indapamide) over hydrochlorothiazide owing to better cardiovascular outcomes. Class I, Level A. 12

ACE Inhibitors

• Grade B recommendation – ACE inhibitors are suitable first‑line monotherapy for non‑Black adults across Canadian, ACC/AHA, and European guidelines. [6][7][8][9]10
• Grade A recommendation against – ACE inhibitors should not be used as first‑line therapy in Black patients because of reduced efficacy; thiazides or calcium‑channel blockers are preferred. Class I, Level A. [6][9]

Angiotensin‑Receptor Blockers (ARBs)

• Grade B recommendation – ARBs are considered equivalent to ACE inhibitors as first‑line agents in all major guidelines. [6][7][8][9]10
• The 2025 AHA/ACC guideline lists ARBs together with thiazides, CCBs, and ACE inhibitors as Class I, Level A first‑line therapy. 13

Calcium‑Channel Blockers (Long‑Acting Dihydropyridines)

• Grade A for isolated systolic hypertension and Grade B for combined systolic/diastolic hypertension across Canadian, ACC/AHA, and European guidelines. [6][7][8][9]10
• The 2025 AHA/ACC guideline recommends long‑acting dihydropyridine CCBs as first‑line agents to prevent cardiovascular disease. Class I, Level A. 13

Beta‑Blockers (Age‑Restricted)

• Grade B recommendation – Beta‑blockers are appropriate first‑line therapy only in patients < 60 years old. [6][7][8][9]10
• Grade A recommendation against – Beta‑blockers should not be used as first‑line agents in patients ≥ 60 years because they are less effective for stroke prevention and overall cardiovascular events. Class I, Level A. [6][9]
• A 2017 ACC/AHA network meta‑analysis demonstrated that beta‑blockers are significantly less effective than thiazides for stroke prevention and cardiovascular outcomes. Level A evidence. 11

Contraindicated or Non‑Preferred First‑Line Agents

• ACE inhibitor + ARB combination – Not recommended (Grade A) due to increased cardiovascular/renal risk. Class I, Level A. [6][7][9][10]
• Alpha‑blockers – Not first‑line (Grade A recommendation against) because they provide inferior cardiovascular disease prevention compared with thiazides. Class I, Level A. [6][9]

Combination Therapy Initiation

• For stage 2 hypertension (BP ≥ 140/90 mmHg or >20/10 mmHg above target), start with two first‑line agents. Grade C (Canadian); Class I, Level B‑R (AHA/ACC 2025). [6][11]13
• Preferred two‑drug combinations:
  
  • Thiazide + ACE inhibitor or ARB
  • Thiazide + CCB
  • CCB + ACE inhibitor or ARB
• The 2024 ESC guideline recommends initiating most patients on a single‑pill combination of two first‑line agents to improve adherence. Class I. 12

First‑Line Antihypertensive Therapy for Adults ≈ 60 Years Old

1. Selection of First‑Line Monotherapy

• Thiazide or thiazide‑like diuretics (chlorthalidone or indapamide) are Grade A first‑line agents in the ACC/AHA, ESC, and Canadian Hypertension Education Program guidelines. [14][15][16][17]
• Chlorthalidone and indapamide are preferred over hydrochlorothiazide because of longer duration of action and superior cardiovascular outcome data. 17
• Long‑acting dihydropyridine calcium‑channel blockers (amlodipine, nifedipine) are Grade A first‑line agents and are especially effective for isolated systolic hypertension. [15][16]17
• ACE inhibitors are Grade B first‑line for non‑Black patients; they are not recommended as first‑line monotherapy in Black patients (Grade A recommendation against) because they achieve ~51 % less stroke‑risk reduction than thiazides or CCBs. [15][16]
• Angiotensin‑receptor blockers are Grade B first‑line agents and are considered clinically equivalent to ACE inhibitors. [15][16]17

2. Agents to Avoid as First‑Line in Patients ≥ 60 Years

• Beta‑blockers are not recommended as first‑line therapy for uncomplicated hypertension in adults ≥ 60 years (Grade A recommendation against) due to inferior stroke and cardiovascular event protection compared with thiazides, CCBs, ACE inhibitors, or ARBs. [15][16]
• Beta‑blockers may be used as first‑line only in patients < 60 years (Grade B) or when compelling indications exist (post‑myocardial infarction, heart‑failure with reduced ejection fraction, angina). [15][16]
• Alpha‑blockers are not recommended as first‑line agents (Grade A) because they provide inferior cardiovascular protection. [15][16]

3. When to Initiate Combination Therapy

• Begin two first‑line agents when systolic BP is ≥ 20 mmHg above target or diastolic BP is ≥ 10 mmHg above target—commonly when BP ≥ 150/90 mmHg while the goal is <130/80 mmHg. [16][17]

4. Preferred Two‑Drug Combinations

• Single‑pill fixed‑dose combinations are strongly preferred to improve medication adherence. 17

5. Contraindicated Drug Combinations

• Do not combine an ACE inhibitor with an ARB (Grade A recommendation against) because of increased risk of hyper‑kalemia, acute kidney injury, and hypotension without added cardiovascular benefit. [16][17]
• Avoid pairing non‑dihydropyridine CCBs (diltiazem, verapamil) with beta‑blockers due to the risk of severe bradycardia and heart block. 16

6. Stepwise Treatment Intensification Algorithm

7. Race‑Specific Considerations

• In Black patients, thiazide diuretics and dihydropyridine CCBs are more effective than ACE inhibitors or ARBs as monotherapy; ACE inhibitors provide ~51 % less stroke‑risk reduction compared with CCBs. [No citation required per instruction]
• ACE inhibitors and ARBs may be used in Black patients as second‑line agents or within combination therapy. 14

8. Clinical Management Pearls

• Avoid clinical inertia: if monotherapy fails to achieve target BP within 4 weeks, promptly add a second agent rather than continuing dose titration of the single drug. 14
• Do not abruptly discontinue antihypertensive therapy without medical supervision, as this can cause rebound hypertension and increase cardiovascular events. 16
• Exercise caution when initiating combination therapy in elderly or frail patients because a rapid, large BP fall may be poorly tolerated. [15][16]

First‑Line Antihypertensive Therapy for Primary Hypertension

Core First‑Line Drug Classes

• The 2025 American College of Cardiology/American Heart Association (ACC/AHA) guideline classifies thiazide or thiazide‑like diuretics, long‑acting dihydropyridine calcium‑channel blockers (CCBs), ACE inhibitors, and angiotensin‑receptor blockers (ARBs) as Class I, Level A first‑line agents for uncomplicated primary hypertension. 19
• High‑quality randomized trials demonstrate that each of these four classes reduces all‑cause mortality, stroke, myocardial infarction, heart failure, and total cardiovascular events compared with placebo. Evidence Level: Class I, Level A (multiple RCTs). [20][19]

Evidence Supporting Thiazide Diuretics

• The 2017 ACC/AHA guideline highlights chlorthalidone as the preferred initial thiazide‑like diuretic because it was the agent used in landmark outcome trials and provides superior cardiovascular protection. Evidence Level: Class I, Level A. 20

Race‑Specific Recommendations

• In patients of African descent, the 2020 International Society of Hypertension (ISH) guideline advises against ACE‑inhibitor or ARB monotherapy; instead, initiate therapy with a thiazide‑type diuretic or a long‑acting dihydropyridine CCB. Evidence Level: Grade A recommendation. [21][22]
• The same ISH guideline recommends an initial combination of a low‑dose ARB + CCB or CCB + thiazide‑like diuretic for Black patients. Evidence Level: Grade A. [21][22]
• The 2017 ACC/AHA guideline similarly states that first‑line treatment for Black patients should include a thiazide‑type diuretic or a CCB. Evidence Level: Grade A. 20

Age‑Specific Recommendations

• The 2015 Canadian Journal of Cardiology (reflecting Canadian guideline consensus) recommends not using beta‑blockers as first‑line therapy in patients ≥ 60 years with uncomplicated hypertension (Grade A). 23
• In older adults, beta‑blockers are significantly less effective than thiazides for stroke prevention and overall cardiovascular event reduction, as shown in a 2018 meta‑analysis. Evidence Level: Class I, Level A. 20

Initiating Combination Therapy

• For stage 2 hypertension (≥ 140/90 mm Hg) or when blood pressure exceeds target by > 20/10 mm Hg, start two first‑line agents, preferably as a single‑pill combination. Evidence Level: Class I, Level B‑R (ACC/AHA 2025). [20][19]
• Single‑pill combinations improve adherence and are strongly preferred, per the 2025 ACC/AHA guideline and a 2022 Journal of the American College of Cardiology (JACC) analysis. Evidence Level: Class I, Level A. [24][19]
• The 2024 European Society of Cardiology (ESC) guideline recommends initiating most patients on dual combination therapy from the outset to enhance blood‑pressure control. Evidence Level: Class I, Level A. 24

Preferred Two‑Drug Combinations

• Thiazide‑type diuretic + ACE inhibitor or ARB – recommended by Canadian consensus (Class I, Level A). 23
• Thiazide‑type diuretic + long‑acting dihydropyridine CCB – recommended by Canadian consensus (Class I, Level A). 23
• Long‑acting dihydropyridine CCB + ACE inhibitor or ARB – endorsed by both the 2022 JACC analysis and Canadian consensus (Class I, Level A/B). [24][23]

Contraindicated Combinations and Agents to Avoid

• Never combine an ACE inhibitor with an ARB – Grade A, Class I, Level A recommendation; the combination raises risks of hyperkalemia, acute kidney injury, syncope, and hypotension without added benefit. Evidence Level: Class I, Level A. [20][23]19
• The 2025 ACC/AHA guideline classifies simultaneous use of ACE inhibitor, ARB, and/or renin inhibitor as Class III (Harm). 19
• Alpha‑blockers should not be used as first‑line therapy (Grade A, Class I). Evidence Level: Class I, Level A. 23
• Non‑dihydropyridine CCBs (diltiazem, verapamil) should not be combined with beta‑blockers because of severe bradycardia and heart‑block risk (Grade A). Evidence Level: Class I, Level A. 23

Stepwise Treatment Algorithm (Stage 1 Hypertension)

Comparative Effectiveness Summary

• Thiazide diuretics possess the most robust mortality and morbidity evidence among first‑line agents; chlorthalidone, in particular, shows strong outcome benefit in landmark trials. Evidence Level: Class I, Level A. 20
• Beta‑blockers are inferior to thiazides, ACE inhibitors, ARBs, and CCBs for stroke prevention and overall cardiovascular event reduction; they should be reserved for patients < 60 years or those with specific compelling indications. Evidence Level: Class I, Level A. 20

First‑Line Treatment for Hypertension

General Recommendations

• Initiate therapy for uncomplicated hypertension with a thiazide or thiazide‑like diuretic (chlorthalidone or indapamide preferred over hydrochlorothiazide), a long‑acting dihydropyridine calcium‑channel blocker, an ACE inhibitor, or an ARB; all four classes provide equivalent cardiovascular protection and carry a Class I, Level A recommendation. European Society of Cardiology (ESC) 2024 and American College of Cardiology/American Heart Association (ACC/AHA) 2025 guidelines support this approach. [25][26]

• The ESC 2024 and ACC/AHA 2025 guidelines converge on the same four major drug classes as first‑line agents for hypertension. [25][26]

Drug‑Class Grading

• Chlorthalidone and indapamide are preferred over hydrochlorothiazide because of longer duration of action and superior cardiovascular outcome data. ESC 2024. 25

Initiation Strategy (Monotherapy vs. Combination)

• Stage 1 hypertension (130–139/80–89 mm Hg) – start with a single first‑line agent; add a second agent only if the target BP < 130/80 mm Hg is not achieved within 4 weeks. ACC/AHA 2018. 26

• Stage 2 hypertension (≥140/90 mm Hg) – initiate two first‑line agents simultaneously, preferably as a single‑pill fixed‑dose combination, to achieve faster control and improve adherence. ESC 2024 and ACC/AHA 2018. [25][26]

• The ESC 2024 guideline recommends upfront combination therapy for most hypertensive patients to enhance BP control and long‑term adherence. 25

Preferred Two‑Drug Combinations

• Thiazide + ACE inhibitor or ARB – Grade A/B.
• Thiazide + long‑acting dihydropyridine CCB – Grade B.

• Long‑acting dihydropyridine CCB + ACE inhibitor or ARB – Grade A/C.

• Single‑pill fixed‑dose combinations are strongly preferred because they simplify treatment, improve adherence, and achieve BP targets more rapidly than separate pills. ESC 2024. 25

Population‑Specific Recommendations

Black Patients

• ACE inhibitors or ARBs are not recommended as first‑line monotherapy (Grade A recommendation against) because they achieve ~51 % less stroke‑risk reduction than thiazides or dihydropyridine CCBs. Canadian Cardiology 2013. 27

• Preferred first‑line agents are thiazide diuretics and long‑acting dihydropyridine CCBs. Canadian Cardiology 2013. 27

• ACE inhibitors and ARBs may be used as second‑line agents or within combination therapy. Canadian Cardiology 2013. 27

Older Adults (≥ 60 years)

• Beta‑blockers are not recommended as first‑line therapy (Grade A recommendation against) because they are less effective at preventing stroke and cardiovascular events than thiazides, CCBs, ACE inhibitors, or ARBs. Canadian Cardiology 2013. 27

• Beta‑blockers remain appropriate for compelling indications (post‑myocardial infarction, heart‑failure with reduced ejection fraction, angina). Canadian Cardiology 2013. 27

Isolated Systolic Hypertension (SBP ≥ 130 mm Hg, DBP < 80 mm Hg)

• Preferred first‑line agents: thiazide or thiazide‑like diuretics (Grade A), long‑acting dihydropyridine CCBs (Grade A), and ARBs (Grade B). Canadian Cardiology 2013. 27

• Beta‑blockers and alpha‑blockers are not recommended as first‑line therapy (Grade A recommendation against). Canadian Cardiology 2013. 27

Agents to Avoid as First‑Line Therapy

• Alpha‑blockers – not recommended (Grade A recommendation against) because they provide inferior cardiovascular protection compared with thiazides. Canadian Cardiology 2013. 27

• Beta‑blockers in patients ≥ 60 years – not recommended (Grade A recommendation against) due to inferior stroke prevention and overall cardiovascular event reduction; may be used in patients < 60 years (Grade B) or when compelling indications exist. Canadian Cardiology 2013. 27

• ACE inhibitors in Black patients – not recommended as first‑line monotherapy (Grade A recommendation against) because of reduced efficacy. Canadian Cardiology 2013. 27

Contraindicated Drug Combinations

• ACE inhibitor + ARB – never combine (Grade A, Class III Harm) due to increased risk of hyperkalemia, acute kidney injury, syncope, and hypotension without added cardiovascular benefit. ESC 2024, ACC/AHA 2018, Canadian Cardiology 2013. [27][25]26

• Non‑dihydropyridine CCB (diltiazem or verapamil) + beta‑blocker – avoid because of risk of severe bradycardia and heart block (Grade A). Canadian Cardiology 2013. 27

Stepwise Treatment Intensification Algorithm

Special Considerations in the Elderly/Frail

• Exercise caution when initiating combination therapy in elderly or frail patients because a rapid, large BP fall may be poorly tolerated. Canadian Cardiology 2013. 27

First‑Line Antihypertensive Therapy Recommendations

Core First‑Line Drug Classes (All Adults)

• The 2025 American College of Cardiology/American Heart Association (ACC/AHA) guideline assigns Class I, Level A evidence to thiazide or thiazide‑like diuretics, long‑acting dihydropyridine calcium‑channel blockers (CCBs), angiotensin‑converting‑enzyme (ACE) inhibitors, and angiotensin‑receptor blockers (ARBs) as interchangeable first‑line options for uncomplicated hypertension【28】.
• Thiazide or thiazide‑like diuretics (chlorthalidone, indapamide preferred over hydrochlorothiazide) receive Grade A recommendation from the Canadian Cardiovascular Society (CCS) based on multiple trials (2008, 2014)【29】【30】.
• Long‑acting dihydropyridine CCBs (amlodipine, nifedipine) are given a Grade A recommendation by the CCS (2014)【30】.
• ACE inhibitors are recommended with Grade B evidence for non‑Black patients (CCS 2008, 2014)【29】【30】.
• ARBs carry a Grade B recommendation (CCS 2008, 2014)【29】【30】.
• Each of these four classes has been shown in randomized controlled trials to reduce cardiovascular events, stroke, and mortality compared with placebo【28】.

Age‑Specific Recommendations

• Patients < 60 years: Any of the four first‑line classes may be used; beta‑blockers are acceptable with Grade B evidence (CCS 2014)【30】.
• Patients ≥ 60 years: Beta‑blockers are not recommended as first‑line therapy (Grade A) because they are significantly less effective for stroke prevention and overall cardiovascular event reduction (CCS 2014)【30】. They remain appropriate only when compelling indications exist (post‑myocardial infarction, heart failure with reduced ejection fraction, angina)【30】.
• Patients ≥ 80 years: Initiate antihypertensive treatment when systolic/diastolic BP is ≥130/80 mm Hg if clinical judgment indicates that benefits outweigh harms (ACC/AHA 2025)【28】.

Race‑Specific Recommendations

• Black patients:
  
  • ACE inhibitors should not be used as first‑line monotherapy (Grade A) because they achieve approximately 51 % less stroke‑risk reduction than thiazides or dihydropyridine CCBs (CCS 2008)【29】.
  • Preferred first‑line agents are thiazide diuretics and long‑acting dihydropyridine CCBs (Grade A)【29】.
  • ACE inhibitors or ARBs may be employed as second‑line agents or as part of combination therapy (CCS 2008)【29】.

Comorbidity‑Specific Recommendations

Diabetes Mellitus (without albuminuria)

• Target blood pressure < 130/80 mm Hg (CCS 2008; 2007)【29】【31】.
• Patients ≥ 55 years: ACE inhibitor (Grade A), ARB (Grade A if left‑ventricular hypertrophy present), dihydropyridine CCB (Grade A), or thiazide diuretic (Grade A) are preferred (CCS 2008; 2007)【29】【31】.
• Patients < 55 years: Same agents are appropriate but supported by Grade B evidence (CCS 2008; 2007)【29】【31】.
• ACE inhibitors and ARBs are highlighted for their additional renal protective effects (CCS 2008; 2007)【29】【31】.

Diabetes Mellitus (with albuminuria)

• Initiate therapy with an ACE inhibitor or ARB (Grade A) (CCS 2008; 2007)【29】【31】.
• If blood pressure remains ≥130/80 mm Hg despite ACE inhibitor/ARB, add a second antihypertensive agent (CCS 2008)【29】.

Isolated Systolic Hypertension (without diabetes)

• Preferred first‑line agents: thiazide or thiazide‑like diuretics, long‑acting dihydropyridine CCBs (Grade A) and ARBs (Grade B) (CCS 2014)【30】.
• Beta‑blockers and alpha‑blockers are not recommended as first‑line therapy (Grade A) (CCS 2014)【30】.

Combination‑Therapy Guidelines

When to Initiate Two Drugs Simultaneously

• For stage 2 hypertension (≥ 140/90 mm Hg) or when systolic BP is ≥20 mm Hg or diastolic BP ≥10 mm Hg above target, start two first‑line agents, preferably as a single‑pill fixed‑dose combination (Class I, Level A) (ACC/AHA 2025)【28】.

Preferred Two‑Drug Combinations

• Single‑pill fixed‑dose combinations are strongly preferred to improve adherence (CCS consensus).

Agents to Avoid as First‑Line Therapy

• Alpha‑blockers are not recommended as first‑line agents (Grade A) because they provide inferior cardiovascular protection compared with thiazides (CCS 2008; 2014)【29】【30】.
• Beta‑blockers in patients ≥ 60 years are not recommended as first‑line therapy (Grade A) (CCS 2014)【30】.
• ACE inhibitors in Black patients are not recommended as first‑line monotherapy (Grade A) (CCS 2008)【29】.

Contraindicated Drug Combinations

• Never combine an ACE inhibitor with an ARB (Grade A, Class III Harm) due to increased risk of hyperkalemia, acute kidney injury, syncope, and hypotension without added cardiovascular benefit (CCS 2014)【30】.
• Do not combine non‑dihydropyridine CCBs (e.g., diltiazem, verapamil) with beta‑blockers because of the risk of severe bradycardia and heart block (Grade A) (CCS 2014)【30】.

Stepwise Treatment Intensification Algorithm

Preferred Thiazide‑like Diuretics for Resistant Hypertension

Choice of Thiazide‑like Diuretics

• In patients with hypertension, chlorthalidone and indapamide are preferred over hydrochlorothiazide because they have a longer duration of action and superior evidence for improving cardiovascular outcomes. 32

Use in Resistant Hypertension

• For individuals whose blood pressure remains uncontrolled despite a three‑drug regimen that includes a diuretic, thiazide‑like diuretics (chlorthalidone or indapamide) are especially recommended owing to their greater antihypertensive efficacy. 32

Initial Antihypertensive Strategy for Stage 2 Hypertension

Initial Combination Therapy – Mandatory for Stage 2 Hypertension

• Stage 2 hypertension (≥140/90 mm Hg) warrants immediate dual‑agent therapy because systolic pressure is ≥20 mm Hg or diastolic pressure ≥10 mm Hg above the target of <130/80 mm Hg (American Family Physician; ACC/AHA). [33][34]
• The ACC/AHA and Canadian Cardiovascular Society recommend starting two first‑line agents right away—either an ACE inhibitor or ARB combined with a thiazide‑like diuretic (chlorthalidone preferred) or a long‑acting dihydropyridine calcium‑channel blocker, preferably as a single‑pill fixed‑dose combination (ACC/AHA 2018; Hypertension 2020). [34][35]

Preferred Two‑Drug Combinations

• ACE inhibitor or ARB + thiazide‑like diuretic (chlorthalidone 12.5–25 mg or indapamide) carries a Grade A/B recommendation in both ACC/AHA and Canadian guidelines (ACC/AHA; Canadian Cardiovascular Society). 36
• Chlorthalidone is superior to hydrochlorothiazide for cardiovascular outcomes and has a longer duration of action (ACC/AHA). 34
• In patients under 55 years who are non‑Black, ACE inhibitors receive a Grade B recommendation as first‑line agents and achieve robust blood‑pressure reductions (Hypertension 2020). 35

Rationale for ACE Inhibitors / ARBs in This Patient

• Non‑Black adults younger than 55 years respond favorably to ACE inhibitor or ARB therapy, making these agents ideal components of combination regimens (Hypertension 2020). 35
• ACE inhibitors and ARBs have Class I, Level A evidence for reducing cardiovascular events, stroke, and mortality in uncomplicated hypertension (ACC/AHA). 34

Target Blood Pressure and Monitoring Timeline

• The therapeutic goal for a middle‑aged adult without comorbidities is <130/80 mm Hg (ACC/AHA; Hypertension 2020). [34][35]
• Blood pressure should be reassessed 2–4 weeks after initiating therapy to gauge response (Hypertension 2020). 35
• The target should be achieved within 3 months of treatment initiation (Hypertension 2020). 35

Agents to Avoid as First‑Line Therapy

• Beta‑blockers are not recommended as first‑line agents in patients younger than 60 years without compelling indications (e.g., post‑MI, heart failure) because they are less effective for stroke prevention and overall cardiovascular outcomes (ACC/AHA). 34
• Alpha‑blockers receive a Grade A recommendation against use as first‑line therapy due to inferior cardiovascular protection compared with thiazide‑like diuretics (ACC/AHA). 34
• Concurrent use of an ACE inhibitor with an ARB is a Class III Harm (contraindicated) because it raises the risk of hyperkalemia, acute kidney injury, and hypotension without added benefit (ACC/AHA). 34
• Hydrochlorothiazide should be avoided when chlorthalidone or indapamide are available, as the latter have superior cardiovascular outcome data (ACC/AHA). 34

Stepwise Intensification if Target Not Achieved

• If blood pressure remains uncontrolled on two agents after 4 weeks, intensify to triple therapy (ACE inhibitor or ARB + dihydropyridine CCB + thiazide‑like diuretic), preferably as a fixed‑dose combination (Hypertension 2020). 35
• For resistant hypertension (uncontrolled on three agents including a diuretic), add spironolactone 25 mg daily as a fourth agent (Hypertension 2020). 35
• If spironolactone is not tolerated, consider alternatives such as amiloride, doxazosin, eplerenone, or clonidine (Hypertension 2020). 35

Guideline Recommendations for Initiating Antihypertensive Therapy

First‑Line Drug Selection and Evidence Level

• For most adults with newly diagnosed hypertension, any of the four first‑line classes—thiazide‑like diuretic, long‑acting dihydropyridine calcium‑channel blocker (CCB), ACE inhibitor, or ARB—provide equivalent cardiovascular protection (Class I, Level A). 37
• In non‑Black adults younger than 60 years, ACE inhibitors and ARBs have Grade B evidence for efficacy. 38
• In Black patients, thiazide‑like diuretics or long‑acting dihydropyridine CCBs are the preferred first‑line monotherapy (Grade A). 37
• ACE inhibitors should not be used as first‑line monotherapy in Black patients (Grade A recommendation against). 37
• In adults aged ≥ 60 years, beta‑blockers are not recommended as first‑line therapy (Grade A recommendation against) because they are less effective for stroke prevention and overall cardiovascular event reduction. [38][37]

Initiation Strategy by Hypertension Stage

• Stage 1 hypertension (130–139 / 80–89 mmHg): start with standard‑dose monotherapy from any first‑line class. 37
• If the target < 130/80 mmHg is not achieved after 4 weeks, add a second first‑line agent rather than simply uptitrating the initial drug. 37
• Stage 2 hypertension (≥ 140/90 mmHg): initiate two first‑line agents simultaneously, preferably as a single‑pill fixed‑dose combination. 37
• Initiating two agents is mandatory when systolic BP is ≥ 20 mmHg above target or diastolic BP is ≥ 10 mmHg above target. 37

Preferred Two‑Drug Combinations

All combinations are supported by the cited evidence. 38

Specific Drug Preferences Within Classes

• Thiazide‑like diuretics: chlorthalidone or indapamide are preferred over hydrochlorothiazide because of longer duration of action and superior cardiovascular outcome data. 37
• The 2017 ACC/AHA guideline specifically highlights chlorthalidone as the optimal first‑step therapy. 37
• Calcium‑channel blockers: long‑acting dihydropyridine CCBs (e.g., amlodipine, nifedipine) are recommended as first‑line agents. 38
• Non‑dihydropyridine CCBs should not be combined with beta‑blockers because of the risk of severe bradycardia and heart‑block (Grade A). 38

Contraindicated Drug Combinations

• Never combine an ACE inhibitor with an ARB (Grade A, Class III Harm) due to increased risk of hyperkalaemia, acute kidney injury, syncope, and hypotension without added cardiovascular benefit. [38][37]
• Avoid combining non‑dihydropyridine CCBs with beta‑blockers because of severe bradycardia and heart‑block risk (Grade A). 38

Agents to Avoid as First‑Line Therapy

• Alpha‑blockers are not recommended (Grade A) because they provide inferior cardiovascular protection compared with thiazides. 37
• Beta‑blockers in patients ≥ 60 years are not recommended (Grade A) owing to inferior stroke prevention. [38][37]
• ACE inhibitors should not be used as first‑line monotherapy in Black patients (Grade A recommendation against). 37

Blood Pressure Targets

• Most adults younger than 65 years: target < 130/80 mmHg (Class I, Level A). 37
• Adults aged ≥ 65 years: systolic target < 130 mmHg if tolerated (Class I, Level A). 37

Dosing and Titration Strategy

• Begin therapy with at least half of the maximum recommended dose to reduce the need for multiple titrations.
• Avoid escalating a single agent to its maximum dose; instead, add a second drug from a different class (Grade B). 38

Special Considerations in Elderly/Frail Patients

• Exercise caution when initiating combination therapy in elderly or frail patients because a rapid, large BP fall may be poorly tolerated. [39][38]
• Do not withhold antihypertensive therapy solely because of age (Grade B). 38

Common Pitfalls to Avoid

• Clinical inertia: most patients will require 2–3 agents; avoid persisting with ineffective monotherapy beyond 4 weeks. 37
• Using hydrochlorothiazide instead of chlorthalidone or indapamide is suboptimal due to inferior cardiovascular outcome data. 37
• Combining an ACE inhibitor with an ARB is a Class III Harm and increases adverse events without benefit. [38][37]